Premium
Long‐term efficacy and safety of the interleukin‐1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma
Author(s) -
Orlando Ida,
Vitale Antonio,
Rigante Donato,
Lopalco Giuseppe,
Fabiani Claudia,
Cantarini Luca
Publication year - 2017
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13538
Subject(s) - medicine , canakinumab , anakinra , dermatology , concomitant , behcet's disease , uveitis , disease , ophthalmology
The authors describe a patient with Behçet's disease treated with anakinra and canakinumab after bladder papillary cancer excision. The same patient had been previously proven to be unresponsive to standard therapy, including TNF-α inhibitors
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom